XRCC4 and ovarian cancer: Our study demonstrates XRCC4 in the NHEJ pathway specifically contributes to platinum resistance by mitigating the DNA damage caused by platinum drugs and provides preclinical evidence for targeting XRCC4 as a new strategy to battle cisplatin resistance in ovarian cancer treatment.